Evidence map›Paper›PMID 31640718›Full record

ArticleRetrovirology2019

Characterization of resistance to a potent D-peptide HIV entry inhibitor.

Amanda R Smith, Matthew T Weinstock, Amanda E Siglin, Frank G Whitby, J Nicholas Francis, Christopher P Hill, Debra M Eckert, Michael J Root, Michael S Kay

Abstract read
In one paragraph

Article in Retrovirology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  4. Article
  5. A targeted covalent small molecule inhibitor of HIV-1 fusion.Chemical communications (Cambridge, England) · 2021
    Article
  6. Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent d-peptide HIV entry inhibitor.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amanda R SmithDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA.
Matthew T WeinstockDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA.
Amanda E SiglinDepartment of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Frank G WhitbyDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA.
J Nicholas FrancisDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA.
Christopher P HillDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA.
Debra M EckertDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA.
Michael J RootDepartment of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Michael S KayDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA. kay@biochem.utah.edu.ORCID 0000-0003-3186-9684

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
Virus TransmissionP50AI150464 · NIAID · UNIVERSITY OF UTAH · PI SUNDQUIST, WESLEY I. · 2019 to 2021
$14.9M
MECHANISMS OF HIV-1 MEMBRANE FUSIONR01GM066682 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI ROOT, MICHAEL JEFFREY · 2002 to 2019
$3.9M
Mechanisms of HIV-1 Env-Mediated Membrane FusionR01AI150490 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI ROOT, MICHAEL JEFFREY · 2020 to 2020
$332k
NCI NIH HHS P30 CA042014NIAID NIH HHS P50 AI150464NIAID NIH HHS R01 AI150490NIGMS NIH HHS P41 GM103393NIGMS NIH HHS R01 GM066682NIH HHS AI076168NIH HHS AI150464NIH HHS AI150490
6 · The paper itself

Abstract

backgroundPIE12-trimer is a highly potent D-peptide HIV-1 entry inhibitor that broadly targets group M isolates. It specifically binds the three identical conserved hydrophobic pockets at the base of the gp41 N-trimer with sub-femtomolar affinity. This extremely high affinity for the transiently exposed gp41 trimer provides a reserve of binding energy (resistance capacitor) to prevent the viral resistance pathway of stepwise accumulation of modest affinity-disrupting mutations. Such modest mutations would not affect PIE12-trimer potency and therefore not confer a selective advantage. Viral passaging in the presence of escalating PIE12-trimer concentrations ultimately selected for PIE12-trimer resistant populations, but required an extremely extended timeframe (> 1 year) in comparison to other entry inhibitors. Eventually, HIV developed resistance to PIE12-trimer by mutating Q577 in the gp41 pocket.

resultsUsing deep sequence analysis, we identified three mutations at Q577 (R, N and K) in our two PIE12-trimer resistant pools. Each point mutant is capable of conferring the majority of PIE12-trimer resistance seen in the polyclonal pools. Surface plasmon resonance studies demonstrated substantial affinity loss between PIE12-trimer and the Q577R-mutated gp41 pocket. A high-resolution X-ray crystal structure of PIE12 bound to the Q577R pocket revealed the loss of two hydrogen bonds, the repositioning of neighboring residues, and a small decrease in buried surface area. The Q577 mutations in an NL4-3 backbone decreased viral growth rates. Fitness was ultimately rescued in resistant viral pools by a suite of compensatory mutations in gp120 and gp41, of which we identified seven candidates from our sequencing data.

conclusionsThese data show that PIE12-trimer exhibits a high barrier to resistance, as extended passaging was required to develop resistant virus with normal growth rates. The primary resistance mutation, Q577R/N/K, found in the conserved gp41 pocket, substantially decreases inhibitor affinity but also damages viral fitness, and candidate compensatory mutations in gp160 have been identified.

Indexed as

Anti-HIV AgentsCell LineDrug Resistance, ViralHIV-1HIV InfectionsHumansMutationPeptidesVirus InternalizationAnti-HIV AgentsPeptidesCompensatory mutationD-peptidegp120gp41HIV entry inhibitionHydrophobic pocketPIE12-trimerViral fitnessViral passagingViral resistance mutation

Identifiers

PMID31640718
PMCPMC6805555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.